Activating the body's backup plan in DMD 👀
At ASGCT 2026, INSERM presented CRISPR-based work in DMD - aiming to switch on utrophin through epigenetic regulation, sparking discussion on mutation-independent strategies and gene regulation tools for muscular dystrophies.
#ASGCT26 #GeneTherapy #MAGIC
At ASGCT 2026, INSERM presented CRISPR-based work in DMD - aiming to switch on utrophin through epigenetic regulation, sparking discussion on mutation-independent strategies and gene regulation tools for muscular dystrophies.
#ASGCT26 #GeneTherapy #MAGIC
May 20, 2026 at 2:51 PM
Activating the body's backup plan in DMD 👀
At ASGCT 2026, INSERM presented CRISPR-based work in DMD - aiming to switch on utrophin through epigenetic regulation, sparking discussion on mutation-independent strategies and gene regulation tools for muscular dystrophies.
#ASGCT26 #GeneTherapy #MAGIC
At ASGCT 2026, INSERM presented CRISPR-based work in DMD - aiming to switch on utrophin through epigenetic regulation, sparking discussion on mutation-independent strategies and gene regulation tools for muscular dystrophies.
#ASGCT26 #GeneTherapy #MAGIC
Meet the Zillow for abandoned gene therapies.
endpoints.news/asgct26-a-zi...
endpoints.news/asgct26-a-zi...
A Zillow-like marketplace for abandoned gene therapies goes live
On Thursday, the American Society of Gene & Cell Therapy (ASGCT) and the Orphan Therapeutics Accelerator (OTXL) debuted a joint clearinghouse for shelved drug programs
endpoints.news
May 15, 2026 at 3:01 PM
Meet the Zillow for abandoned gene therapies.
endpoints.news/asgct26-a-zi...
endpoints.news/asgct26-a-zi...
I've got several more stories for you too, including my latest on two nonprofit organizations that have created a joint venture dubbed CGTxchange to help abandoned cell and gene therapies find a new home. #ASGCT2026 endpoints.news/asgct26-a-zi...
A Zillow-like marketplace for abandoned gene therapies goes live
On Thursday, the American Society of Gene & Cell Therapy (ASGCT) and the Orphan Therapeutics Accelerator (OTXL) debuted a joint clearinghouse for shelved drug programs
endpoints.news
May 15, 2026 at 12:13 PM
I've got several more stories for you too, including my latest on two nonprofit organizations that have created a joint venture dubbed CGTxchange to help abandoned cell and gene therapies find a new home. #ASGCT2026 endpoints.news/asgct26-a-zi...
Two #ASGCT26 oral presentations tomorrow!
🔹Engineering CasX for therapeutic-grade in vivo editing with DeepXE, a predictive model for guide potency
🔹ADDing a lock to epigenome editing: DNMT3A allostery enhances specificity and potency of CRISPR-CasX-based epigenetic repressors
🔹Engineering CasX for therapeutic-grade in vivo editing with DeepXE, a predictive model for guide potency
🔹ADDing a lock to epigenome editing: DNMT3A allostery enhances specificity and potency of CRISPR-CasX-based epigenetic repressors
May 14, 2026 at 5:35 PM
Two #ASGCT26 oral presentations tomorrow!
🔹Engineering CasX for therapeutic-grade in vivo editing with DeepXE, a predictive model for guide potency
🔹ADDing a lock to epigenome editing: DNMT3A allostery enhances specificity and potency of CRISPR-CasX-based epigenetic repressors
🔹Engineering CasX for therapeutic-grade in vivo editing with DeepXE, a predictive model for guide potency
🔹ADDing a lock to epigenome editing: DNMT3A allostery enhances specificity and potency of CRISPR-CasX-based epigenetic repressors
We made it to Boston for #ASGCT2026! Join trusted experts from IDT at Danaher booth #1337 to discover how our capabilities drive gene editing from design to delivery. We’re excited to welcome you!
#ASGCT #ASGCT26 #CRISPR #geneediting
#ASGCT #ASGCT26 #CRISPR #geneediting
May 12, 2026 at 1:45 PM
We made it to Boston for #ASGCT2026! Join trusted experts from IDT at Danaher booth #1337 to discover how our capabilities drive gene editing from design to delivery. We’re excited to welcome you!
#ASGCT #ASGCT26 #CRISPR #geneediting
#ASGCT #ASGCT26 #CRISPR #geneediting
So our anti-HIV CAR makes it to the NYT. LV from Miltenyi, funded by CIRM @cirmnews.bsky.social - article should also highlight Dr Abedi’s team @ucdavismedschool.bsky.social @ucdavis.bsky.social where patients are being treated. #HIVcure #HIV #ASGCT26
www.nytimes.com/2026/05/11/h...
www.nytimes.com/2026/05/11/h...
A Single Infusion Could Suppress H.I.V. for Years, Study Suggests
www.nytimes.com
May 12, 2026 at 12:29 PM
So our anti-HIV CAR makes it to the NYT. LV from Miltenyi, funded by CIRM @cirmnews.bsky.social - article should also highlight Dr Abedi’s team @ucdavismedschool.bsky.social @ucdavis.bsky.social where patients are being treated. #HIVcure #HIV #ASGCT26
www.nytimes.com/2026/05/11/h...
www.nytimes.com/2026/05/11/h...
Check out our full #ASGCT26 agenda for the week here: www.businesswire.com/news/home/20...
www.businesswire.com
May 11, 2026 at 2:37 PM
Check out our full #ASGCT26 agenda for the week here: www.businesswire.com/news/home/20...
Feed: "Oncology News, Insights, Stories by OncoDaily"
Published on Sunday, April 5, 2026
Published on Sunday, April 5, 2026
New AgenT-797 Data to Highlight Immune Modulation at ASGCT26 – MiNK Therapeutics
New AgenT-797 Data to Highlight Immune Modulation at ASGCT26 - MiNK Therapeutics / American Society of Gene and Cell Therapy, ASGCT26, cancer, MiNK
oncodaily.com
April 5, 2026 at 5:21 AM
Feed: "Oncology News, Insights, Stories by OncoDaily"
Published on Sunday, April 5, 2026
Published on Sunday, April 5, 2026